文献速递血栓与止血贫血与红细胞疾病

评估镰状细胞病人群中的血栓预防:弥合证据缺口

Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.
PubMed 文献 · Br J Haematol · 2024-04-05

镰状细胞病(SCD)由β-珠蛋白基因突变引起,2021年全球估计约50万受影响新生儿,美国则影响不足20万人。突变血红蛋白S在低氧下聚合致红细胞镰变,引发血管闭塞、溶血性贫血、炎症和器官损伤。文献提示SCD存在高凝状态,凝血级联持续激活导致血栓栓塞事件,尤其静脉血栓栓塞(VTE)在成人和儿童SCD中均与死亡率增加独立相关。虽然SCD人群VTE风险增加似乎已明确,但缺乏该人群血栓预防指南。本文描述SCD高凝状态和血栓风险增加,并倡导制定循证指南以助预防SCD中的VTE。

要点

  • SCD由β-珠蛋白基因突变引起,2021年全球估计约50万受影响新生儿。
  • SCD存在高凝状态,凝血级联持续激活导致血栓栓塞事件。
  • VTE在成人和儿童SCD中均与死亡率增加独立相关。

核心结论

  • SCD人群VTE风险增加似乎已明确,但缺乏血栓预防指南。
  • 本文倡导制定循证指南以助预防SCD中的VTE。

研究设计与样本

  • 本文为Wider Perspective(宽视角)文章,描述SCD高凝状态和血栓风险增加并倡导制定循证指南。

主要发现

  • SCD由β-珠蛋白基因突变引起,2021年全球估计约50万受影响新生儿,美国影响不足20万人。
  • 突变血红蛋白S在低氧条件下易聚合,致红细胞镰变,引发血管闭塞、溶血性贫血、炎症和器官损伤。
  • 文献提示SCD存在高凝状态,凝血级联持续激活导致血栓栓塞事件。
  • VTE在成人和儿童SCD中均与死亡率增加独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) arises from beta-globin gene mutations, with global estimates indicating around 500 000 affected neonates in 2021. In the United States, it is considered rare, impacting fewer than 200 000 individuals. The key pathogenic flaw lies in mutant haemoglobin S, prone to polymerization under low oxygen conditions, causing erythrocytes to adopt a sickled shape. This leads to complications like vascular occlusion, haemolytic anaemia, inflammation and organ damage. Beyond erythrocyte abnormalities however, there is a body of literature highlighting the hypercoagulable state that is likely a contributor to many of the complications we see in SCD. The persistent activation of the coagulation cascade results in thromboembolic events, notably venous thromboembolism (VTE) which is independently associated with increased mortality in both adults and children with SCD. While the increased risk of VTE in the SCD population seems well established, there is a lack of guidelines for thromboprophylaxis in this population. This Wider Perspective will describe the hypercoagulable state and increased thrombosis risk in the SCD population, as well as advocate for the development of evidence-based guidelines to aid in the prevention of VTE in SCD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Davila J, O'Brien SH, Mitchell WB, et al. Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap. Br J Haematol. 2024. PMID: 38578212. doi:10.1111/bjh.19428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。